Yu‐Yuan Chiu

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects

Hironobu Tsukada, Yu‐Luan Chen, Guangqing Xiao, Lisa Lennek et autres

Ulotaront is a novel psychotropic agent with agonist activity at trace amine-associated receptor 1 (TAAR1) and 5-hydroxytryptamine type 1A (5-HT 1A ) receptors in phase III clinical development for the treatment of schizophrenia. This study aimed to investigate the effect of paroxetine, …

jp, us (code pays fourni par la source)

Comparison of pharmacokinetics of apomorphine (sublingual film or subcutaneous injection) between patients with Parkinson's disease in Europe and North America

Felix Agbo, Scott J. Brantley, Jie Hu, Yu‐Yuan Chiu et autres

us, de, it (code pays fourni par la source)

Population pharmacokinetics model of apomorphine (sublingual film or subcutaneous injection) in healthy subjects and patients with Parkinson’s disease (updated)

Felix Agbo, Ryan L. Crass, Yu‐Yuan Chiu, Sunny Chapel et autres

us (code pays fourni par la source)

Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson’s Disease and “OFF” Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study

Felix Agbo, Stuart Isaacson, Ramon Gil, Yu‐Yuan Chiu et autres

In a pivotal study, apomorphine sublingual film (APL; KYNMOBI ® ) was an effective and generally well-tolerated on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD), approved across the dose range of 10–30 mg. Pharmacokinetics and comparative bioavailability of APL …

us (code pays fourni par la source)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease

Felix Agbo, Ryan L. Crass, Yu‐Yuan Chiu, Sunny Chapel et autres

Abstract Apomorphine is an on‐demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD). A joint parent‐metabolite population pharmacokinetic (PK) model characterized apomorphine and apomorphine‐sulfate following administration of apomorphine sublingual film (APL) and two formulations of subcutaneous apomorphine. Overall, 2485 samples …

us (code pays fourni par la source)

Exposure-response efficacy model of apomorphine sublingual film for the on-demand treatment of “OFF” episodes in patients with Parkinson's disease

Felix Agbo, Yu‐Yuan Chiu, Sunny Chapel, Bradford Navia

us (code pays fourni par la source)

Population Pharmacokinetics Model of Apomorphine/Apomorphine-Sulphate Administered as a Sublingual Film or Subcutaneously in Healthy Subjects and Patients With Parkinson’s Disease (P3.8-034)

Felix Agbo, Howard N. Bockbrader, Yu‐Yuan Chiu, Sunny Chapel et autres

A population pharmacokinetics (popPK) model was developed to characterize the PK of apomorphine and its major metabolite, apomorphine-sulfate, in healthy subjects and patients with Parkinson’s disease (PD) following administration of apomorphine sublingual film (APL) and subcutaneously injected apomorphine.

us (code pays fourni par la source)

1.40 Lurasidone Exposure Response in Pediatric Bipolar Depression: Simulation and Comparison to Adults

Sunny Chapel, Yu‐Yuan Chiu, Jong-Tae Lee, Felix Agbo et autres

us, gb (code pays fourni par la source)

Lurasidone Dose Response in Bipolar Depression: A Population Dose-response Analysis

Sunny Chapel, Yu‐Yuan Chiu, Jay Hsu, Josephine Cucchiaro et autres

PURPOSE: Characterization of dose-response relationships for psychotropic agents may be difficult to determine based on results of individual clinical studies, particularly those with a flexible dose design. The goal of this pharmacometric analysis was to characterize the dose-response profile for lurasidone in …

gb, us (code pays fourni par la source)

Lurasidone drug-drug interaction studies: a comprehensive review

Yu‐Yuan Chiu, Larry Ereshefsky, Sheldon Preskorn, Nagaraju Poola et autres

BACKGROUND: To evaluate potential drug-drug interactions with the atypical antipsychotic lurasidone. METHODS: Seven phase I studies were conducted to investigate the effects of repeated dosing of ketoconazole, diltiazem, rifampin, or lithium on the pharmacokinetics (PK) of single oral doses of lurasidone, or …

us (code pays fourni par la source)

Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open‐label, crossover studies

Sheldon Preskorn, Larry Ereshefsky, Yu‐Yuan Chiu, Nagaraju Poola et autres

OBJECTIVE: This study aimed to investigate the effect of prandial status and caloric and fat composition of meals on the pharmacokinetics of lurasidone. METHODS: Two randomized, open-label, crossover studies were conducted in clinically stable adults with schizophrenia or schizoaffective disorder. Study 1 …

us, gb (code pays fourni par la source)

Assessment of the effect of ethnicity on linifanib tolerability and pharmacokinetics in patients with cancer.

Jianping Xiong, Yu‐Yuan Chiu, R. Pradhan, X. Li et autres

e13082 Background: Linifanib is a novel orally active, potent and selective vascular endothelial growth factor receptor and platelet derived growth factor receptor kinase inhibitor. Linifanib activity as a monotherapy has been demonstrated in phase 1 and 2 trials in patients with a …